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A B S T R A C T
Surgery is potentially curative for primary nonmetastatic extremity soft tissue sarcomas. After
surgery alone, patientsmay remain at risk for local recurrences and/or metastatic disease. To reduce
the likelihood of a local relapse, the addition of radiotherapy (RT) to limb-sparing surgerymay result in
higher local control rates of at least 85%. Generally, it can be stated that local control after both
preoperative and postoperative RT is comparable, but that preoperative RT comes with a more
favorable toxicity profile after prolonged follow-up, albeit at the cost of a higher wound complication
rate. Furthermore, recent data suggest that preoperative RT is more cost effective. To reduce the
risk of subsequent metastatic disease, systemic chemotherapy can be introduced early during the
primary management of these patients. These systemic chemotherapy regimens can also be
applied both preoperatively and postoperatively. Finally, with the aim of increasing the antitumor
response of perioperative RT, these agents may even be combined with RT, concurrently and
sequentially. While designing new preoperative combination regimens, responses should be
carefully monitored by both sophisticated radiologic and pathologic evaluations. This article reviews
all these aspects, in addition to limb-sparing surgery.
J Clin Oncol 36:118-124. © 2017 by American Society of Clinical Oncology
INTRODUCTION
The role of surgery aiming to cure primary non-
metastatic extremity soft tissue sarcomas (ESTS), is
undebated. However, the addition of radiotherapy
(RT) to limb-sparing surgery may result in higher
local control rates of at least 85%, especially when
resection margins are negative, compared with
surgery alone.1-4 This combinedmodality approach,
as indicated by both National Comprehensive
Cancer Network5 and European Society for Medical
Oncology guidelines,6 has widely replaced the need
for amputations.7
Predominantly dependent on age, histologic
subtype, grade, and size, a substantial proportion
of patients may develop subsequent metastatic
disease.8 Attempts have been made to reduce this
risk by the introduction of systemic chemo-
therapy early during the primary management
of these patients. With the aim of increasing
the antitumor response of perioperative RT, these
agents may even be combined with RT, concur-
rently and sequentially. These aspects should be
thoroughly discussed before management by
experienced multidisciplinary teams in referral
hospitals. Careful investigations on radiologic and
pathologic response evaluation are mandatory,
especially when new preoperative combination
regimens are designed.
Timing of Perioperative RT
On the basis of the results of the Canadian
SR-2 trial1 and other nonrandomized comparisons,9,10
it can be stated that local control after both pre-
operative and postoperative RT is comparable.
Recent data suggest that preoperative RT is more
cost effective.11 The following sections discuss the
main differences between both approaches.
Postoperative RT
Conventionally, the postoperative RT regi-
men consists of two phases. First, the entire
operative bed (with a margin) is irradiated to
50 Gy in 1.8-2 Gy fractions followed by a boost of
10-16 Gy to the tumor site before surgery. Details
on this regimen have been described previously.2
Because postoperative RT combines both large
volumes and high doses, the long-term results
include higher rates of permanent and progressive
morbidities, such as fibrosis, joint stiffness, and
edema12 compared with patients treated with
preoperative RT. Albeit, the incidence of early
wound complications is lower.1 Studies from both
Scandinavia13 and France14 have questioned the
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gain in local control by the 10-16 Gy boost after R0 resections.
Currently, the question of timing is being investigated by the
NCT02565498 study, which is a randomized trial comparing
50 Gy preoperative RT with 50 Gy postoperative RT after an R0
resection.
Preoperative RT
For preoperative RT, the volume of tissue irradiated is smaller,
and the dose delivered is lower than during postoperative RT.
Specifically, the tumor (plus a margin) is irradiated to 50 Gy in 1.8-2
Gy fractions. Although this regimen has been shown to result in an
increased incidence of (sometimes severe) wound healing prob-
lems,1 these complications are of a temporary nature. Conversely, the
permanent long-term complications of fibrosis, joint stiffness, and
edema are reduced with preoperative RT compared with post-
operative RT.12 Moreover, with the sarcoma in situ during pre-
operative RT, the opportunity arises to investigate individual and
histotype-specific regimens with respect to fraction size, total dose,
and combination with radiosensitizers.
In the past, several preoperative RT regimens with un-
conventional fraction sizes and/or total doses other than 50 Gy
have been investigated, each with their own wound complication
and local control profiles. Temple et al15 observed a relatively low
wound complication rate of 15%, while maintaining local control
at 97% at 5 years of follow-up after 10 3 3 Gy. Between 1974 and
1987, Eilber et al16 performed three consecutive phase II studies, all
applying 3.5 Gy fraction sizes. They eventually concluded the 83 3.5
Gy schedule provided themost favorable balance of local control and
wound healing rates.16,17 In all these schedules, intra-arterial or
intravenous doxorubicinwas delivered during RT. Themost extreme
hypofractionation schedule to date is the Polish 5 3 5 Gy pre-
operative schedule, which enrolled 272 patients and reported
a local control rate of 81% at 3 years.18
The histologic subtype myxoid liposarcoma is known for its
exceptional radiation sensitivity, demonstrated by high local control
rates after 50 Gy preoperatively.19 On the basis of this finding, an
international prospective phase II clinical trial (NCT02106312) is
investigating the efficacy of a reduced dose of 18 3 2 Gy for this
subtype.
Experience with carcinomas has demonstrated that, com-
pared with RT alone, concurrent regimens of preoperative (or
definitive) RT in combination with systemic agents may result in
improved local control and, sometimes, survival (albeit at the risk
of an increased acute toxicity profile). Similar concurrent regimens
have been explored for sarcomas aiming to increase antitumor efficacy
and/or to use concurrent systemic agents as a means to lower the
concurrent RT dose. Examples of tested combinations are ifosfamide
2,500mg/m2 per day for 5 days (+ 83 3.5 Gy20), epirubicin 30mg/m2
per day, and ifosfamide 2,500 mg/m2 per day, both on days 1 to 4
(+ 8 3 3.5 Gy21). Biologically more interesting are studies with tar-
geted agents, such as bevacizumab in combinationwith 283 1.8 Gy,22
sorafenib either in combinationwith 83 3.5 Gy23 or with 253 2Gy,24
pazopanib with 253 2 Gy,25 and sunitinib in combination with 50 to
50.4 Gy.26,27 Except for concurrent single-agent ifosfamide, all these
schedules seem to be associated with pathologic (near) complete
response rates significantly higher than the 8% to 10% rates his-
torically observed after RTalone, as listed in Table 1.28,29 However, it
is important to point out that for soft tissue sarcoma (STS),
pathologic response is not yet a valid surrogate end point.31 Of more
clinical relevance are parameters such as local control and overall
survival (OS), but they take years to mature. For now, outside the
setting of well-designed prospective clinical trials, the 1.8-2 Gy
fraction regimens should be considered the standard of care.
Preoperative RT: Balancing Local Control and Surgical
Complications
The use of preoperative RT has offered new possibilities in
limb salvage. After neoadjuvant therapy, narrow margins against
critical structures can be allowed, while maintaining local control
and functional outcome after resection3,32,33 because local control
after both preoperative and postoperative RTseems comparable.1,9,10
An increased local control rate has been observed delivering pre-
operative RTwhen such an expected positive margin against critical
structures is planned and expected. This has also been observed in
Table 1. Preoperative RT Series With Respect to Concurrent Systemic Therapy: Local Control and Histologic Response Rates Compared With RT Only




at NN Years (near) pCR, %
RT only O’Sullivan1 94* 25 3 2 Gy — 92 at 6.9 † —
Canter28 25 25 3 2 Gy — 100 at 3 8
Shah29 30 25 3 2 Gy — 100 at 5 10
RT plus conventional
chemotherapy
MacDermed20 34 8 3 3.5 Gy Ifosfamide 89 at 5 11.8
Ryan21 25 8 3 3.5 Gy Epirubicin plus /ifosfamide 88 at 2 40
Gronchi30 135 25 3 2 Gy Epirubicin plus ifosfamide 95.2 at 10 —
RT plus targeted
agents
Yoon22 20 28 3 1.8 Gy Bevacizumab 95 at 2 20
Meyer23 16 8 3 3.5 Gy Sorafenib 100 at 2 44
Canter24 8 25 3 2 Gy Sorafenib 100 at 3 38
Haas25 11 25 3 2 Gy Pazopanib 91 at 2 40
Jakob26 9 28 3 1.8 Gy Sunitinib 88 at 3 33
Lewin27 9 28 3 1.8 Gy Sunitinib ‡ §
Abbreviations: (near) pCR, defined as more than 95% necrosis; NN, specified number of years follow-up; pCR, pathologic complete response; RT, radiotherapy.
*Preoperative RT arm only.
†Update at ASCO and Connective Tissue Oncology Society presentations in 2004.
‡At 3.7 years median follow-up, five of nine had local relapses.
§Median percentage of necrosis was 75%; range, 1% to 95%, suggestive of a (near) pCR rate of 0%.
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a recent trial combining preoperative chemotherapy and RT in high-
risk STS after prolonged follow-up.30,34 Early wound healing
difficulties are the disadvantage of this multimodality treatment
strategy.1,35,36 Comparing results of prospective and retrospective
studies, it must be noted that wound complications may occur in
up to 42% of patients treated without (neo)adjuvant RT.3,37-40 The
Canadian SR-2 trial reported a significantly higher wound compli-
cation rate after neoadjuvant RT (17% v 35%), especially in the lower
extremity (20% v 43%).1 Comparable rates were observed in a study
of patients. 70 years old (40% v 19%), with a particular emphasis to
the adductor compartment and the groin.41
In the modern era, the incidence of wound complications
within a phase III study combining RT with anthracycline plus
ifosfamide neoadjuvant chemotherapy in localized extremity or
trunk wall STS was less than 20%, whereas that of neoadjuvant
chemotherapy followed by adjuvant external beam RT was 10%.42
Commonly, wound healing problems in low-risk patients are delayed
and can be expected on average 3 weeks after surgery.35 When
present, they are often successfully treated with modern wound
healing strategies, such as vacuum treatment, and can therefore be
regarded as temporary. Significant wound healing problems ne-
cessitating additional surgical intervention are uncommon.43,44
Although fully acknowledging the acute toxicity profile of
preoperative RT as described above, two merits should be high-
lighted. First, long-term toxicity results are in support of neoadjuvant
RT because less edema and fibrosis, fewer fractures, and supe-
rior limb function are reported.12,45 Second, preoperative RT may
compensate for (anticipated) R1 resections.46-49 Furthermore, the
acute toxicity profile inherent in preoperative RT can bemitigated by
experienced surgeons in tertiary referral centers, using techniques
such as free and pedicle flaps for high-risk locations (recurrences,
large tumors, and lower extremity locations, especially in the ad-
ductor compartment and the groin).43,44,50,51
The patient’s age and comorbidities should also influence
decision making, because older age, obesity, vascular insufficiency,
smoking, and diabetes have a negative effect on wound healing.
Finally, some histologic subtypes are more sensitive than others (ie,
myxoid liposarcoma, solitary fibrous tumor, extraskeletal myxoid
chondrosarcoma, etc.), whereas some others have a higher local
recurrence risk (ie, myxofibrosarcoma and malignant peripheral
nerve sheath tumors).52,53
When a decision for RT is made, timing should be influenced
by tumor characteristics, such as presentation (need to preserve
function or not), site of origin, histologic subtype, and malignancy
grade and size, as well as the patient’s characteristics, as mentioned
above. The balance of pros and cons might increasingly favor the
use of preoperative RT, where its toxicities should be manageable in
experienced centers.
Timing of Perioperative Systemic Therapy: Adjuvant
Chemotherapy
For many bone tumors, perioperative chemotherapy is the
standard of care. However, adjuvant chemotherapy has failed to
prove an unequivocal clinical benefit in the heterogeneous group of
STS. Nevertheless, the high rate of local or distant relapse and
ultimate mortality (approximately 50% for high-grade tumors),
even after adequate local treatment of STS,54 has inevitably
sustained the clinical interest of using adjuvant chemotherapy toward
improving recurrence-free survival (RFS) and overall survival (OS).
An attempt to systematically analyze data on adjuvant che-
motherapy, overcoming the problem of inadequately powered
small trials and minimizing potential biases, was the 1997 Sarcoma
Meta-Analysis Collaboration (SMAC).55 This landmark examination
is the only STS meta-analysis to date on the basis of individual
patient data. SMAC suggested adjuvant chemotherapy to signifi-
cantly improve local and distant recurrence-free intervals (4% at
10 years), especially for men and ESTS (7% at 10 years; HR, 0.80;
P = .029). Pervaiz et al56 updated this meta-analysis in 2008, adding
another four trials, confirming the marginal efficacy of doxorubicin-
based adjuvant chemotherapy.
After SMAC, the Italian Randomized Cooperative Trial,57
involving 104 high-grade patients with ESTS, studied an intensified
adjuvant epirubicin/ifosfamide treatment arm (total cycle dose of
ifosfamide, 9 g/m2). After amedian follow-up of 59months, the study
showed a significant improvement inmedian RFS andOS; however, it
was not sustained at longer follow-up.
The most recent adjuvant chemotherapy trial, coordinated by
the European Organization for Research and Treatment of Cancer-
Soft Tissue and Bone Sarcoma Group (EORTC-STBSG), is the
largest conducted to date. This study, involving 351 patients, failed
to demonstrate any impact of adjuvant chemotherapy (five cycles
of doxorubicin/ifosfamide) on either RFS or OS, especially after R0
resections.58,59
These trials should be included in newmeta-analyses. Until then,
adjuvant chemotherapy has not reproducibly improved RFS or OS in
an unselected patient population, as listed in Table 2. Whether ad-
juvant chemotherapy can be proposed to high-risk individual patients
in still-to-be-determined subtypes is a matter of shared decision
making.6 New drugs, including novel molecularly driven agents, have
been introduced in the treatment arena of STS. Future adjuvant
chemotherapy trials with the same regimen for all STS subtypes are
undeniably over. They should be driven by yet-to-be-identified and
validated prognostic biomarkers. Options are (1) randomized trials in
selected groups of histologic subtypes with specific systemic agents,
(2) conventional chemotherapy in several STSs but with a specific
molecular signature,61 and (3) selected regimens according to pathway
signatures (eg, adjuvant imatinib in GI stromal tumors62).
Induction (Neoadjuvant) Chemotherapy: Is It Better
Than Adjuvant?
For locally advanced STS, options to be discussed include
neoadjuvant chemotherapy (NACT) with adequately dosed
anthracyclines plus ifosfamide,63 isolated limb perfusion, or regional
hyperthermia combined with chemotherapy.64,65
Several phase II trials have evaluated NACT combined with RT
in series of up to 70 to 80 patients.66 However, lacking randomi-
zation, the exact benefit of these strategies in terms of progression-
free survival and the percentage of patients achieving limb-sparing
resections has not been prospectively addressed. The only randomized
trial comparing NACT followed by surgery with surgery only, re-
ported by the EORTC-STBSG, failed to demonstrate a significant
tumor control rate or survival advantage.67
Finally, a large prospective trial compared three cycles of
a conventional, full-dosed, anthracycline-ifosfamide (EI) regimen
120 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Haas et al
Downloaded from ascopubs.org by Leids Univers Medisch Centrum on October 7, 2019 from 145.088.209.033
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
with histotype-tailored chemotherapy (HT-CT) in localized, high-
grade,. 5-cm, adult ESTS,60 aiming to reduce the relapse risk with
the HT-CT regimen by 30%. The HT-CT regimen in the experi-
mental arm was based on results observed in the advanced setting
during the last decade.42 After a median follow-up of more than
1 year, unexpectedly, patients receiving EI experienced a better
prognosis. The projected RFS at 4 years was 62% with the EI
regimen versus 38% in the experimental arm. After 70 events, at
the third preplanned interim analysis, the study was closed. The
results observed in the experimental arm are surprising. Whatever
the hypotheses, EI compared with HT-CT is still superior in most
common subtypes of localized STS.
Referral to specialized centers of all patients with (suspected)
STS will help to develop precision medicine programs to identify
new actionable targets and new ambitious programs, even in the
context of localized diseases.68-71 The collection of fresh/frozen tissue
and tumor imprints is encouraged because newmolecular pathology
assessments could be made at a later stage in the patient’s interest.










No. 1,568 104* 351 819 287
Median follow-up 9.4 years 59 months (minimum
observation period
36 months)
7.99 years 8.2 years 12.3 months
Drugs Doxorubicin based† Per course: epirubicin
120 mg/m2 1
ifosfamide 9 g/m2; total
5 courses
Per course: doxorubicin
75 mg/m2 1 ifosfamide
5 g/m2; total 5 courses.
For 62931: doxorubicin
75 mg/m2 1 ifosfamide
5 g/m2, total 5






Local RFI HR, 0.73 (0.56 to 0.94);
P 5 .016
— — — 85% v 86% at 46 months
Absolute local relapse-
free benefit at NN
years (CI)
6% at 10 years (1% to
10%)
0% v 10% at 2 years
(P 5 .02), 6% v 17%
at 4 years (P 5 .09)
18.9% v 23.7% at 5 years —
Distant RFI HR, 0.70 (0.57 to 0.85);
P 5 .0003
— — — HR, 2.147 (1.172 to
3.930); P 5 .011
Absolute distant
relapse-free benefit
at NN years (CI)
10% at 10 years (5% to
15%)
28% v 45% at 2 years
(P5 .08), 44% v 45% at
4 years (P 5 0.94)
— — 45% v 74% at 46 months
Overall RFI HR, 0.75 (0.64 to 0.87);
P , .001
HR, 0.59 (0.36 to 0.99);
P 5 .04





at NN years (CI)
10% at 10 years (5% to
15%)
27% at 2 years, 13% at
4 years
— —
Overall survival HR, 0.89 (0.76 to 1.03);
P 5 .12
HR, 0.52 (0.29 to 0.93);
P 5 .03
HR, 0.94 (0.68 to 1.31),
P 5 .72
— HR, 2.687 (1.104 to




4% at 10 years (1% to 9%) 13% at 2 years, 19% at
4 years; P 5 .04
After marginal resection:
27.6% v 44.7% at





regardless of sex or age
64% v 89% at 46 months
Subgroup analyses Men benefit more than
women; extremities
benefit more than other
locations
No significant differences
for age, sex, center of
surgery, histology,




























in all strata except for
high-grade myxoid
liposarcoma
DI Average median relative
DI: 83.3%, 63% of
cycles at DI $ 80%,
48% of cycles at DI $
90%
80% completed full 5
cycles, 68% received




10% v 18% dose
reductions
Abbreviations: CYVADIC, doxorubicin 50 mg/m² day 1, dacarbazine 400 mg/m² days 1-3, cyclophosphamide 500mg/m² day 1, and vincristine 1.5 mg/m² day 1; DI, dose
intensity; EORTC-STBSG, European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; HR, hazard ratio; NN, specified number of
years follow-up; RFI, recurrence-free interval; SMAC, Sarcoma Meta-analysis Collaboration.
*Preplanned interim analysis revealed benefit for chemotherapy, P 5 .001.
†Doxorubicin dose per study predominantly 50-70 mg/m² and cumulative 400-550 mg.
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Pathologic Response Evaluation After Preoperative
Therapy
Whereas several clinical trials have demonstrated the rele-
vance of histopathologic appearance in bone sarcomas, mainly in
osteosarcomas and Ewing sarcomas, it is still under debate whether
there should be a comparable response evaluation scheme for STS.
Generally accepted rules on how the tumor specimen should be
worked up after preoperative treatment and how the results should
be reported are lacking. However, the EORTC-STBSG has proposed
a standardized protocol for neoadjuvant therapy response assessment
on the basis of a consensus of their STS experienced reference pa-
thologists. They proposed a five-tier histologic response score on the
basis of the percentage of remaining stainable tumor cells ranging
from zero to . 50%.72 Subsequently, this proposed response score
was assessed for its prognostic value by another group at Harvard
Medical School in Boston.31 In this retrospective study of 100 patients
with STS treated with preoperative RT, The EORTC-STBSG response
score was not found to be prognostic, but the extent of hyalinization
and fibrosis was associated with a favorable outcome. These results
can only be viewed as hypothesis generating, and a prospective trial
with well-defined criteria for specimen analysis is necessary.
Furthermore, after neoadjuvant treatment, it is difficult if not
impossible to evaluate whether areas of necrosis are the result of the
treatment or have been a consequence of insufficient blood supply
due to insufficient neovascularization. Therefore, it seems to be more
effective to estimate the percentage of remaining tumor cells, although
their tumorigenic capability cannot be seen under the microscope. In
summary, a prospective clinical trial including high-grade sarcomas
in defined locations that are evaluated by a consensus protocol de-
veloped by a group of pathologists will be the only way to clarify the
relevance of preoperative neoadjuvant treatment.
Radiologic Response Evaluation After Preoperative
Therapy
Magnetic resonance imaging (MRI) is standard imaging be-
fore and after RT. However, histopathologic changes that occur
after RT confound dimension-based assessments of response.
Except for myxoid liposarcoma,73 significant dimensional radio-
logic responses after preoperative RTare rare events and have been
reported to be as low as 0%.28 Consequently, dimension-based
assessments have been shown to have no correlation with outcome
or histopathologic response,74,75 and alternative response assess-
ments are needed. Tumor characteristics on computed tomography
scans (such as the Choi criteria) or tumor contrast enhancement at
MRI may complement tumor size as a criterion to better predict
pathologic response. In a study of neoadjuvant chemotherapy or
chemoradiotherapy response to chemotherapy with or without RT
was associated with a better outcome in patients with high-risk STS,
and Choi criteria were better predictors than conventional Response
Evaluation Criteria In Solid Tumors.76,77 Although in standard
clinical practice, post-RT imaging of the primary sarcoma is unlikely
to alter the decision regarding operability,78 evolving therapeutic
options do require a robust assessment of response and clinical trials
necessitate quantitative measurements.
Current consensus from the EORTC-STBSG suggests that the
addition of functional diffusion-weighted MRI (DW-MRI) to stan-
dard anatomic and postcontrast MRI greatly facilitates interpretation
because the combination of reduced enhancement and increasing
apparent diffusion coefficient (ADC) may increase confidence for
response.79 After RT, new enhancement alone should be inter-
preted with caution because this may be a result of vascular dis-
ruption rather than histologic response. Moving forward into
clinical trials, DW-MRI is also promising as a quick, noninvasive
tool showing excellent reproducibility for ADC measurements,
which reflect tumor cellularity and microarchitecture in STS
(coefficient of variation [CoV], 1.7%).80 Preclinical data suggest
that DW-MRI may also be valuable in assessments as early as 2 days
after RT.81 ADC can be supplemented with quantitative measures
of perfusion, such as enhancing fraction (CoV, 8.6%), or model-
based measures, such as Ktrans (CoV, 13.9%).82 Dual baseline
quantitative MRI allows individual patient response assessments
rather than cohort measures, which may not reflect response in
heterogeneous patient groups. However, the relationship of these
MRI parameter changes with clinical outcomes has not yet been
validated; therefore, their use as clinical trial end points must be
carefully considered and used in conjunction with proven end
points (such as local control and survival). Alternative methods of
assessment are also poorly understood; however, a small study of
[18F]fluorodeoxyglucose positron-emission tomography/computed
tomography in high-grade sarcomas did show some promise for
fluorodeoxyglucose uptake measurements of standardized uptake
value.83
In conclusion, nonmetastatic sarcomas should be surgically
removed whenever possible. Perioperatively, the addition of RT
and/or chemotherapy should be considered, on the basis of both
tumor and patient characteristics. With respect to radiation, ap-
plying RT preoperatively should be considered. These discussions
should take place between patients and experienced teams in
tertiary referral centers. Treatment-related early end points, such as
radiologic and histologic response, are appealing and should be
included in future prospective trials to assess for correlations with
clinical outcomes, such as local control and survival.
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